Linifanib

被引：13
作者：
不详
机构：
来源：
Drugs in R & D | 2010年 / 10卷 / 2期
关键词：
Breast-cancer; Colorectal-cancer; general; Linifanib; Liver-cancer; Non-small-cell-lung-cancer; Research-and-; development; treatment;
D O I：
10.2165/11584520-000000000-00000
中图分类号：
学科分类号：
摘要：
Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. It was being developed by Roche but development has now reverted to Abbott. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. This review discusses the key development milestones and therapeutic trials of this drug. © 2010 Adis Data Information BV. All rights reserved.
引用
收藏
页码：111 / 122
页数：11
相关论文
共 21 条
  • [1] Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology, (2007)
  • [2] Rugo H.S., Lopez-Hernandez J., Gomez-Villanueva A., Et al., ABT-869 in combination with paclitaxel (P) as first-line treatment in patients (Pts) with advanced breast cancer, 32nd Annual San Antonio Breast Cancer Symposium, (2009)
  • [3] Toh H., Chen P., Carr B.I., Et al., Linifanib phase II trial in patients with advanced hepatocellular carcinoma, 46th Annual Meeting of the American Society of Clinical Oncology, (2010)
  • [4] Soo R.A., Goss G.D., Salgia R., Et al., Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results, 46th Annual Meeting of the American Society of Clinical Oncology, (2010)
  • [5] Tan E., Salgia R., Besse B., Et al., ABT-869 in non-small cell lung cancer: Interim results, 45th Annual Meeting of the American Society of Clinical Oncology, (2009)
  • [6] Tannir N.M., Wong Y., Kollmannsberger C.K., Et al., Phase II trial of linifanib in patients with advanced renal cell cancer after sunitinib failure, 46th Annual Meeting of the American Society of Clinical Oncology, (2010)
  • [7] Hernandez J.E., Zape J., Glaser K., Et al., Multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis and suppresses proliferation of Ba/F3 FLT-3 ITD mutant cells in vitro and in vivo through inhibition of FLT3 and AKT, 50th Annual Meeting and Exposition of the American Society of Hematology, (2008)
  • [8] Humerickhouse R., Gupta N., Goh B., Et al., Phase 1 comparison of pharmacokientics, safety and efficacy with low versus high doses of ABT-869 in refractory solid tumors, 33rd Congress of the European Society for Medical Oncology, (2008)
  • [9] Steinberg J., Tan E., Wei-Peng Y., Et al., Preliminary analysis of ABT-869 safety, pharmacokinetics and efficacy in three phase 2 solid tumor studies, 33rd Congress of the European Society for Medical Oncology, (2008)
  • [10] Tamura T., Yamamoto N., Nokihara H., Et al., A Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors, 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, (2009)
123